JP2014528480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528480A5 JP2014528480A5 JP2014535897A JP2014535897A JP2014528480A5 JP 2014528480 A5 JP2014528480 A5 JP 2014528480A5 JP 2014535897 A JP2014535897 A JP 2014535897A JP 2014535897 A JP2014535897 A JP 2014535897A JP 2014528480 A5 JP2014528480 A5 JP 2014528480A5
- Authority
- JP
- Japan
- Prior art keywords
- unit
- cancer
- attachment
- point
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 claims 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010016626 Dipeptides Proteins 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- GDIHDSKOVXEJQQ-UHFFFAOYSA-N NC(O)=O.NC(O)=O.NC(O)=O.N Chemical group NC(O)=O.NC(O)=O.NC(O)=O.N GDIHDSKOVXEJQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547192P | 2011-10-14 | 2011-10-14 | |
| US61/547,192 | 2011-10-14 | ||
| PCT/US2012/059867 WO2013055990A1 (en) | 2011-10-14 | 2012-10-12 | Pyrrolobenzodiazepines and targeted conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018107170A Division JP7123635B2 (ja) | 2011-10-14 | 2018-06-04 | ピロロベンゾジアゼピンおよび標的コンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014528480A JP2014528480A (ja) | 2014-10-27 |
| JP2014528480A5 true JP2014528480A5 (OSRAM) | 2015-12-03 |
| JP6393617B2 JP6393617B2 (ja) | 2018-09-19 |
Family
ID=48082465
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535897A Active JP6393617B2 (ja) | 2011-10-14 | 2012-10-12 | ピロロベンゾジアゼピンおよび標的コンジュゲート |
| JP2018107170A Active JP7123635B2 (ja) | 2011-10-14 | 2018-06-04 | ピロロベンゾジアゼピンおよび標的コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018107170A Active JP7123635B2 (ja) | 2011-10-14 | 2018-06-04 | ピロロベンゾジアゼピンおよび標的コンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9526798B2 (OSRAM) |
| EP (2) | EP3388435B1 (OSRAM) |
| JP (2) | JP6393617B2 (OSRAM) |
| CN (2) | CN103987384A (OSRAM) |
| CA (1) | CA2850373C (OSRAM) |
| ES (2) | ES2687246T3 (OSRAM) |
| WO (1) | WO2013055990A1 (OSRAM) |
Families Citing this family (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| NZ602932A (en) | 2010-04-15 | 2014-08-29 | Seattle Genetics Inc | Targeted pyrrolobenzodiazapine conjugates |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| MX341524B (es) | 2011-09-20 | 2016-08-24 | Medimmune Ltd | Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos. |
| AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
| EP2751110B1 (en) * | 2011-10-14 | 2017-04-19 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| KR101891859B1 (ko) | 2011-10-14 | 2018-08-24 | 메디뮨 리미티드 | 피롤로벤조디아제핀 |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| SMT201800346T1 (it) | 2012-10-12 | 2018-09-13 | Medimmune Ltd | Coniugati pirrolobenzodiazepina-anticorpo |
| EP2906249B1 (en) * | 2012-10-12 | 2018-06-27 | MedImmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014057122A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| SI2906253T1 (sl) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo proti PSMA |
| PT2906298T (pt) | 2012-10-12 | 2018-12-28 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpos |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| ES2713164T3 (es) | 2012-10-12 | 2019-05-20 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| CN110627797A (zh) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| JP6307519B2 (ja) | 2012-12-21 | 2018-04-04 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびその結合体 |
| JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| DK2968494T3 (en) | 2013-03-13 | 2019-03-04 | Seattle Genetics Inc | ACTIVATED CARBON FILTERING FOR CLEANING BENZODIAZEPINE ADCs |
| EP2968596B1 (en) | 2013-03-13 | 2019-03-06 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| KR102274714B1 (ko) | 2013-03-13 | 2021-07-09 | 씨젠 인크. | 사이클로덱스트린 및 항체-약물 포합체 제형 |
| EA038512B1 (ru) | 2013-03-15 | 2021-09-08 | Регенерон Фармасьютикалз, Инк. | Конъюгаты майтанзиноидов и их терапевтическое применение |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| CA2921412C (en) | 2013-08-26 | 2024-05-28 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| NZ758050A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| HK1222577A1 (zh) | 2013-12-16 | 2017-07-07 | Genentech Inc. | 擬肽化合物及其抗體藥物偶聯物 |
| US11116847B2 (en) | 2013-12-19 | 2021-09-14 | Seagen Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
| KR102399005B1 (ko) | 2014-03-11 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 항-egfrviii 항체 및 그것의 용도 |
| RS58440B1 (sr) | 2014-04-11 | 2019-04-30 | Medimmune Llc | Konjugovana jedinjenja koja sadrže cistein-projektovana antitela |
| KR101628872B1 (ko) * | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| PE20170935A1 (es) | 2014-09-12 | 2017-07-13 | Genentech Inc | Anticuerpos anti-her2 e inmunoconjugados |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| PE20171185A1 (es) | 2015-01-14 | 2017-08-22 | Bristol Myers Squibb Co | Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso |
| US9527871B2 (en) | 2015-01-14 | 2016-12-27 | Bristol-Myers Squibb Company | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
| WO2016160615A1 (en) | 2015-03-27 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CA2990030A1 (en) | 2015-06-23 | 2016-12-29 | Bristol-Myers Squibb Company | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses |
| CA2987641A1 (en) | 2015-07-06 | 2017-01-12 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| EP3165237B1 (en) | 2015-11-03 | 2018-12-19 | Industrial Technology Research Institute | Antibody-drug conjugate (adc) and method for forming the same |
| SI3380124T1 (sl) | 2015-11-25 | 2024-10-30 | Legochem Biosciences, Inc. | Konjugati, ki obsegajo samožrtvujoče skupine in z njimi povezani postopki |
| US11173214B2 (en) | 2015-11-25 | 2021-11-16 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
| KR102847348B1 (ko) | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | 펩타이드 그룹을 포함하는 접합체 및 이와 관련된 제조방법 |
| ES2919323T3 (es) | 2015-12-04 | 2022-07-26 | Seagen Inc | Conjugados de compuestos de tubulisina cuaternizados |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| GB201521709D0 (en) * | 2015-12-09 | 2016-01-20 | Kings College London And Sec Dep For Health The | PBD Antibacterial agents |
| JP2018536682A (ja) | 2015-12-11 | 2018-12-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法 |
| MX390630B (es) | 2016-01-25 | 2025-03-21 | Regeneron Pharma | Derivados de maitansinoide, conjugados de los mismos y metodos de uso. |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| JP7073266B2 (ja) | 2016-03-25 | 2022-05-23 | シージェン インコーポレイテッド | Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| TW201808936A (zh) | 2016-05-18 | 2018-03-16 | 美商梅爾莎納醫療公司 | 吡咯并苯并二氮呯類及其共軛物 |
| US10526294B2 (en) | 2016-06-24 | 2020-01-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| TW201811376A (zh) | 2016-07-01 | 2018-04-01 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 抗體-藥物結合物及使用其之治療方法 |
| MA46417A (fr) | 2016-09-23 | 2019-07-31 | Regeneron Pharma | Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations |
| RS63660B1 (sr) | 2016-09-23 | 2022-11-30 | Regeneron Pharma | Anti-muc16 (mucin 16) antitela |
| JP2019530707A (ja) | 2016-10-10 | 2019-10-24 | セレラント セラピューティクス インコーポレイテッド | イソキノリジノベンゾジアゼピン（ｉｑｂ）−１（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール（ｃｂｉ）二量体 |
| GB201617466D0 (en) * | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| MY199937A (en) | 2016-11-08 | 2023-11-29 | Regeneron Pharma | Steroids and protein-conjugates thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| GB201619490D0 (en) * | 2016-11-17 | 2017-01-04 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| CN118562004A (zh) | 2016-12-16 | 2024-08-30 | 蓝鳍生物医药公司 | 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法 |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| ES2871001T3 (es) | 2017-02-08 | 2021-10-28 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| CN110352074B (zh) | 2017-02-28 | 2024-07-16 | 思进股份有限公司 | 用于偶联的半胱氨酸突变抗体 |
| KR102648564B1 (ko) | 2017-03-24 | 2024-03-19 | 씨젠 인크. | 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물 |
| AU2018246806B2 (en) | 2017-03-29 | 2022-05-12 | Ligachem Biosciences Inc. | Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof |
| WO2018192944A1 (en) | 2017-04-18 | 2018-10-25 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| WO2018213082A1 (en) | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| KR20200007905A (ko) | 2017-05-18 | 2020-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | 사이클로덱스트린 단백질 약물 접합체 |
| BR112019025888A2 (pt) | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
| ES2988683T3 (es) | 2017-06-14 | 2024-11-21 | Adc Therapeutics Sa | Pautas posológicas para la administración de un CAF anti-CD19 |
| KR102736878B1 (ko) | 2017-06-23 | 2024-12-05 | 벨로스바이오 인코포레이티드 | Ror1 항체 면역접합체 |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| SG11202000358YA (en) | 2017-08-18 | 2020-02-27 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201714115D0 (en) | 2017-09-04 | 2017-10-18 | Femtogenix Ltd | Cytotoxic agents |
| AU2018342527B2 (en) | 2017-09-29 | 2024-06-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| AU2018346507B2 (en) | 2017-10-04 | 2025-03-13 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| CN111601619A (zh) | 2017-11-07 | 2020-08-28 | 里珍纳龙药品有限公司 | 用于抗体药物偶联物的亲水性连接体 |
| CN111417409B (zh) | 2017-11-14 | 2022-07-08 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂䓬缀合物 |
| WO2019104289A1 (en) | 2017-11-27 | 2019-05-31 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| KR20250148679A (ko) | 2017-12-06 | 2025-10-14 | 어비디티 바이오사이언시스 인크. | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 |
| JP2021506883A (ja) | 2017-12-21 | 2021-02-22 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピン抗体結合体 |
| US12070506B2 (en) | 2018-01-08 | 2024-08-27 | Regeneron Pharmaceuticals, Inc. | Steroids and antibody-conjugates thereof |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| WO2019189453A1 (en) | 2018-03-28 | 2019-10-03 | Mitsubishi Tanabe Pharma Corporation | DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP3788075A1 (en) | 2018-04-30 | 2021-03-10 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof |
| AU2019265703A1 (en) | 2018-05-09 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
| EP3790591A4 (en) | 2018-05-09 | 2022-05-11 | LegoChem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
| MY206284A (en) | 2018-05-17 | 2024-12-06 | Regeneron Pharma | Anti-cd63 antibodies, conjugates, and uses thereof |
| CA3120528A1 (en) | 2018-11-20 | 2020-05-28 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists |
| IL319265A (en) | 2018-12-21 | 2025-04-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and their uses |
| SG11202106658XA (en) | 2018-12-21 | 2021-07-29 | Regeneron Pharma | Rifamycin analogs and antibody-drug conjugates thereof |
| CN113454097B (zh) | 2018-12-21 | 2024-08-30 | 里珍纳龙药品有限公司 | 微管溶素及蛋白质-微管溶素偶联物 |
| KR20200084802A (ko) * | 2019-01-03 | 2020-07-13 | 주식회사 레고켐 바이오사이언스 | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 |
| JP2022517767A (ja) | 2019-01-08 | 2022-03-10 | レゲネロン ファーマシューティカルス，インコーポレーテッド | 無痕跡型リンカー及びそのタンパク質－コンジュゲート |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| JP2022523360A (ja) | 2019-02-21 | 2022-04-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｅｔに結合する抗ｍｅｔ抗体および二特異性抗原結合分子を使用した眼癌の治療方法 |
| MX2021010477A (es) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. |
| EP3959319A4 (en) | 2019-04-25 | 2023-06-07 | Avidity Biosciences, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS FOR MULTI-EXON SKIPPING |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US11578090B2 (en) | 2019-06-06 | 2023-02-14 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| CA3142337A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Una amidites and uses thereof |
| KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| WO2021080608A1 (en) | 2019-10-25 | 2021-04-29 | Medimmune, Llc | Branched moiety for use in conjugates |
| CN115348874A (zh) | 2020-01-24 | 2022-11-15 | 里珍纳龙药品有限公司 | 蛋白质-抗病毒化合物偶联物 |
| MX2022010599A (es) | 2020-02-28 | 2022-09-09 | Regeneron Pharma | Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos. |
| IL296387B2 (en) | 2020-03-19 | 2024-08-01 | Avidity Biosciences Inc | Preparations and methods for the treatment of facial, back and arm muscle atrophy |
| MX2022011880A (es) | 2020-03-27 | 2022-10-20 | Avidity Biosciences Inc | Composiciones y metodos para tratar distrofia muscular. |
| KR20230004651A (ko) | 2020-04-16 | 2023-01-06 | 리제너론 파마슈티칼스 인코포레이티드 | 딜스-알더 접합 방법 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| BR112022024361A2 (pt) | 2020-06-24 | 2022-12-27 | Regeneron Pharma | Tubulisinas e conjugados de proteína-tubulisina |
| BR112023000489A2 (pt) | 2020-07-13 | 2023-03-28 | Regeneron Pharma | Análogos de camptotecina conjugados a um resíduo de glutamina em uma proteína, e seu uso |
| US12280124B2 (en) | 2020-09-14 | 2025-04-22 | Regeneron Pharmaceuticals, Inc. | Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof |
| IL301702A (en) | 2020-10-22 | 2023-05-01 | Regeneron Pharma | Anti-FGFR2 antibodies and methods of using them |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| US20250026838A1 (en) | 2021-07-13 | 2025-01-23 | Truebinding, Inc. | Methods of preventing protein aggregation |
| US20250041433A1 (en) | 2021-07-28 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Protein-antiviral compound conjugates |
| KR20240055874A (ko) | 2021-09-16 | 2024-04-29 | 어비디티 바이오사이언시스 인크. | 안면견갑상완 근이영양증을 치료하는 조성물 및 방법 |
| US20230279120A1 (en) | 2021-11-09 | 2023-09-07 | Truebinding, Inc. | Methods of treating or inhibiting cardiovascular diseases |
| AU2022422149A1 (en) | 2021-12-23 | 2024-08-01 | Mirecule, Inc. | Compositions for delivery of polynucleotides |
| WO2023129518A1 (en) | 2021-12-29 | 2023-07-06 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
| US20230287138A1 (en) | 2022-01-12 | 2023-09-14 | Regneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| AU2023208050A1 (en) | 2022-01-14 | 2024-07-04 | Regeneron Pharmaceuticals, Inc. | Verrucarin a derivatives and antibody drug conjugates thereof |
| CN119072335A (zh) | 2022-03-11 | 2024-12-03 | 瑞泽恩制药公司 | 包含glp1肽模拟物的抗glp1r抗体-药物缀合物及其用途 |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| EP4512410A1 (en) | 2022-04-07 | 2025-02-26 | Twinpig Biolab, Inc. | Novel-peptide-based anticancer immunotherapeutic agent |
| EP4548932A1 (en) | 2022-06-30 | 2025-05-07 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| CN120239705A (zh) | 2022-07-21 | 2025-07-01 | 萤火虫生物股份有限公司 | 糖皮质激素受体激动剂和其缀合物 |
| CN120659627A (zh) | 2022-07-29 | 2025-09-16 | 瑞泽恩制药公司 | 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法 |
| JP2025538220A (ja) | 2022-11-14 | 2025-11-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法 |
| KR20250128394A (ko) | 2022-11-30 | 2025-08-27 | 리제너론 파마슈티칼스 인코포레이티드 | Tlr7 작용제 및 이의 항체-약물-접합체 |
| KR20250133813A (ko) | 2022-12-21 | 2025-09-08 | 리제너론 파마슈티칼스 인코포레이티드 | Adc 접합을 위한 토포이소머라아제 i 억제제의 전구약물 및 이의 사용 방법 |
| CN121001751A (zh) | 2023-02-09 | 2025-11-21 | 里珍纳龙药品有限公司 | 借助逆电子需求狄尔斯-阿尔德反应的抗体-药物缀合物 |
| EP4601703A1 (en) | 2023-04-18 | 2025-08-20 | Astrazeneca AB | Conjugates comprising cleavable linkers |
| CN121039163A (zh) | 2023-05-02 | 2025-11-28 | 瑞泽恩制药公司 | 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途 |
| US12491257B2 (en) | 2023-06-27 | 2025-12-09 | Avidity Biosciences, Inc. | Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates |
| WO2025007063A1 (en) | 2023-06-30 | 2025-01-02 | Avidity Biosciences, Inc. | Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| US20250171516A1 (en) | 2023-11-03 | 2025-05-29 | Regeneron Pharmaceuticals, Inc. | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof |
| WO2025117727A1 (en) | 2023-11-29 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361742A (en) | 1964-12-07 | 1968-01-02 | Hoffmann La Roche | 5-oxo-1h-pyrrolo-[2, 1-c][1, 4]-benzodiazepin-2-crylamides |
| US3523941A (en) | 1967-03-06 | 1970-08-11 | Hoffmann La Roche | Benzodiazepine compounds and process for their preparation |
| US3524849A (en) | 1967-10-27 | 1970-08-18 | Hoffmann La Roche | Process for the preparation of pyrrolo-benzodiazepine acrylamides and intermediates useful therein |
| JPS4843755B1 (OSRAM) | 1969-06-26 | 1973-12-20 | ||
| IL33558A (en) | 1968-12-30 | 1973-10-25 | Fujisawa Pharmaceutical Co | Antibiotic pyrrolo-benzodiazepine compound,its derivatives and processes for their production |
| FR2027356A1 (en) | 1968-12-30 | 1970-09-25 | Fujisawa Pharmaceutical Co | Benzodiazepinone antibiotics |
| JPS5382792U (OSRAM) | 1976-12-10 | 1978-07-08 | ||
| JPS6053033B2 (ja) | 1976-12-28 | 1985-11-22 | 財団法人微生物化学研究会 | 新制癌抗生物質マゼスラマイシン及びその製造方法 |
| JPS585916B2 (ja) | 1977-12-27 | 1983-02-02 | 株式会社ミドリ十字 | 新規ベンゾジアゼピン系化合物 |
| JPS5615289A (en) | 1979-07-17 | 1981-02-14 | Green Cross Corp:The | Novel benzodiazepinnbased compound 3 |
| JPS57131791A (en) | 1980-12-31 | 1982-08-14 | Fujisawa Pharmaceut Co Ltd | Benzodiazepine derivative and its preparation |
| JPH0353356Y2 (OSRAM) | 1981-02-06 | 1991-11-21 | ||
| CA1184175A (en) | 1981-02-27 | 1985-03-19 | Walter Hunkeler | Imidazodiazepines |
| CA1185602A (en) | 1981-02-27 | 1985-04-16 | Emilio Kyburz | Imidazodiazepines |
| CA1173441A (en) | 1981-02-27 | 1984-08-28 | Hoffmann-La Roche Limited | Imidazodiazepines |
| JPS58180487A (ja) | 1982-04-16 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 抗生物質ｄｃ−８１およびその製造法 |
| JPS58180487U (ja) | 1982-05-28 | 1983-12-02 | 松下電工株式会社 | 光線式報知器の組立体 |
| US4427588A (en) | 1982-11-08 | 1984-01-24 | Bristol-Myers Company | Process for conversion of oxotomaymycin to tomaymycin |
| US4427587A (en) | 1982-11-10 | 1984-01-24 | Bristol-Myers Company | Total synthesis of antitumor antibiotics BBM-2040A and BBM-2040B |
| JPS59152329A (ja) | 1983-02-17 | 1984-08-31 | Green Cross Corp:The | 局所障害抑制剤 |
| FR2586683B1 (fr) | 1985-08-29 | 1988-07-01 | Centre Nat Rech Scient | Nouveaux derives de neothramycine, leur procede de preparation et leur application en tant que medicaments |
| JP2660201B2 (ja) | 1988-08-05 | 1997-10-08 | 塩野義製薬株式会社 | 新規ピロロ［１，４］ベンゾジアゼピン誘導体および老人性痴呆薬 |
| FR2676230B1 (fr) | 1991-05-07 | 1993-08-27 | Centre Nat Rech Scient | Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant. |
| GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
| FR2696176B1 (fr) | 1992-09-28 | 1994-11-10 | Synthelabo | Dérivés de pipéridine, leur préparation et leur application en thérapeutique. |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| GB9316162D0 (en) | 1993-08-04 | 1993-09-22 | Zeneca Ltd | Fungicides |
| JP4568429B2 (ja) | 1998-07-08 | 2010-10-27 | イー インク コーポレイション | マイクロカプセル化された電気泳動デバイスにおいて改良されたカラーを得る方法 |
| GB9818732D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collection of compounds |
| DK1413582T3 (da) | 1998-08-27 | 2006-07-17 | Spirogen Ltd | Dimere pyrrolobenzodiazepiner |
| GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| US6909006B1 (en) | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
| EP1320522B8 (en) | 2000-09-19 | 2006-02-01 | Moses Lee | Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| US6660856B2 (en) | 2002-03-08 | 2003-12-09 | Kaohsiung Medical University | Synthesis of pyrrolo[2,1-c][1,4]benzodiazepine analogues |
| SI2357006T1 (sl) | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni |
| US20040138269A1 (en) | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| EP1608664B1 (en) | 2003-03-31 | 2009-01-28 | Council of Scientific and Industrial Research | Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| ATE516288T1 (de) | 2003-10-22 | 2011-07-15 | Us Gov Health & Human Serv | Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren |
| GB0416511D0 (en) | 2003-10-22 | 2004-08-25 | Spirogen Ltd | Pyrrolobenzodiazepines |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| ES2398975T3 (es) * | 2004-03-01 | 2013-03-25 | Spirogen Sàrl | Derivados de 11-hidroxi-5H-pirrolo[2,1-c][1,4]benzodiazepin-5-ona como intermedios clave para la preparación de pirrolobenzodiazepinas sustituidas en C2 |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0404574D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Amino acids |
| DE102004010943A1 (de) | 2004-03-03 | 2005-09-29 | Degussa Ag | Verfahren zur Herstellung von N-geschützten 4-Ketprolinderivaten |
| JP5166861B2 (ja) | 2004-03-09 | 2013-03-21 | スピロゲン リミティッド | ピロロベンゾジアゼピン |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| EP1831418A2 (en) | 2004-12-24 | 2007-09-12 | Showa Denko Kabushiki Kaisha | Production method of thermoelectric semiconductor alloy, thermoelectric conversion module and thermoelectric power generating device |
| JP5122441B2 (ja) | 2005-04-19 | 2013-01-16 | シアトル ジェネティックス， インコーポレイテッド | ヒト化抗ｃｄ７０結合剤およびその使用 |
| SI1879901T1 (sl) | 2005-04-21 | 2010-04-30 | Spirogen Ltd | Pirolobenzodiazepini |
| ATE427949T1 (de) | 2005-10-05 | 2009-04-15 | Spirogen Ltd | 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung |
| US20070154906A1 (en) | 2005-10-05 | 2007-07-05 | Spirogen Ltd. | Methods to identify therapeutic candidates |
| DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
| ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| WO2008050140A2 (en) | 2006-10-27 | 2008-05-02 | Spirogen Limited | Compounds for treatment of parasitic infection |
| CA2699837C (en) | 2006-12-01 | 2017-06-13 | Seattle Genetics, Inc. | Variant target binding agents and uses thereof |
| SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
| GB0722088D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0722087D0 (en) | 2007-11-09 | 2007-12-19 | Spirogen Ltd | Polyamides |
| CA2718942A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819097D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP3100745B1 (en) | 2009-02-05 | 2018-04-18 | Immunogen, Inc. | Novel benzodiazepine derivatives |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| JP2013505944A (ja) * | 2009-09-24 | 2013-02-21 | シアトル ジェネティックス， インコーポレイテッド | Ｄｒ５リガンド薬物結合体 |
| EP2534158B1 (en) | 2010-02-09 | 2014-01-08 | Bristol-Myers Squibb Company | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| NZ602932A (en) | 2010-04-15 | 2014-08-29 | Seattle Genetics Inc | Targeted pyrrolobenzodiazapine conjugates |
| EP2675479B1 (en) | 2011-02-15 | 2016-01-13 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| MX341524B (es) | 2011-09-20 | 2016-08-24 | Medimmune Ltd | Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos. |
| EA029046B1 (ru) | 2011-10-14 | 2018-02-28 | Медимьюн Лимитед | Пирролобензодиазепины и промежуточные соединения для их получения, способы их синтеза |
| KR101891859B1 (ko) | 2011-10-14 | 2018-08-24 | 메디뮨 리미티드 | 피롤로벤조디아제핀 |
| SG11201401406YA (en) | 2011-10-14 | 2014-05-29 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP2751110B1 (en) | 2011-10-14 | 2017-04-19 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative and autoimmune diseases |
| AU2012322613B2 (en) | 2011-10-14 | 2016-04-21 | Medimmune Limited | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| AU2013255613B2 (en) | 2012-04-30 | 2017-06-22 | Medimmune Limited | Pyrrolobenzodiazepines |
| CN104540827B (zh) | 2012-04-30 | 2018-03-23 | Ucl商业有限公司 | 吡咯并苯并二氮杂卓 |
| AU2013288930A1 (en) | 2012-07-09 | 2014-12-04 | Genentech, Inc. | Immunoconjugates comprising anti-CD79b antibodies |
| SG11201500087VA (en) | 2012-07-09 | 2015-02-27 | Genentech Inc | Immunoconjugates comprising anti-cd22 antibodies |
| KR20150039818A (ko) | 2012-08-02 | 2015-04-13 | 제넨테크, 인크. | 항-etbr 항체 및 면역접합체 |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
| ES2713164T3 (es) | 2012-10-12 | 2019-05-20 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| HRP20171264T1 (hr) | 2012-10-12 | 2017-10-20 | Adc Therapeutics Sa | Konjugati protutijela anti-her2-pirolobenzodiazepina |
| WO2014057118A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| WO2014057122A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| SI2906253T1 (sl) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo proti PSMA |
| EP2906249B1 (en) | 2012-10-12 | 2018-06-27 | MedImmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| PT2906298T (pt) | 2012-10-12 | 2018-12-28 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpos |
| SMT201800346T1 (it) | 2012-10-12 | 2018-09-13 | Medimmune Ltd | Coniugati pirrolobenzodiazepina-anticorpo |
| JP6307519B2 (ja) | 2012-12-21 | 2018-04-04 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンおよびその結合体 |
| CN110627797A (zh) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| ES2731681T3 (es) | 2013-02-22 | 2019-11-18 | Abbvie Stemcentrx Llc | Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos |
| JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びそのコンジュゲート |
| EP2968596B1 (en) | 2013-03-13 | 2019-03-06 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| AU2014230735B2 (en) | 2013-03-13 | 2018-03-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014174111A1 (en) | 2013-04-26 | 2014-10-30 | Pierre Fabre Medicament | Axl antibody-drug conjugate and its use for the treatment of cancer |
| US20160256561A1 (en) | 2013-10-11 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| HK1222577A1 (zh) | 2013-12-16 | 2017-07-07 | Genentech Inc. | 擬肽化合物及其抗體藥物偶聯物 |
| GB201406767D0 (en) | 2014-04-15 | 2014-05-28 | Cancer Rec Tech Ltd | Humanized anti-Tn-MUC1 antibodies anf their conjugates |
-
2012
- 2012-10-12 CA CA2850373A patent/CA2850373C/en active Active
- 2012-10-12 EP EP18168997.7A patent/EP3388435B1/en active Active
- 2012-10-12 CN CN201280062295.4A patent/CN103987384A/zh active Pending
- 2012-10-12 EP EP12840661.8A patent/EP2755642B1/en active Active
- 2012-10-12 US US14/351,168 patent/US9526798B2/en active Active
- 2012-10-12 JP JP2014535897A patent/JP6393617B2/ja active Active
- 2012-10-12 ES ES12840661.8T patent/ES2687246T3/es active Active
- 2012-10-12 ES ES18168997T patent/ES2945932T3/es active Active
- 2012-10-12 CN CN201810169400.3A patent/CN108164551A/zh active Pending
- 2012-10-12 WO PCT/US2012/059867 patent/WO2013055990A1/en not_active Ceased
-
2016
- 2016-06-14 US US15/181,900 patent/US9713647B2/en active Active
-
2017
- 2017-06-27 US US15/635,063 patent/US10328084B2/en active Active
-
2018
- 2018-06-04 JP JP2018107170A patent/JP7123635B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528480A5 (OSRAM) | ||
| JP2014534200A5 (OSRAM) | ||
| JP2022017296A5 (OSRAM) | ||
| JP2020525429A5 (OSRAM) | ||
| JP2017095457A5 (OSRAM) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| Wang et al. | Mesoporous silica nanoparticles with lactose-mediated targeting effect to deliver platinum (iv) prodrug for liver cancer therapy | |
| JP2014528467A5 (OSRAM) | ||
| JP2017537080A5 (OSRAM) | ||
| JP2016503414A5 (OSRAM) | ||
| JP2019501204A5 (OSRAM) | ||
| IL266563B (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| RU2013109143A (ru) | Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы | |
| JP2008505167A5 (OSRAM) | ||
| JP2017536344A5 (OSRAM) | ||
| JP2010501572A5 (OSRAM) | ||
| JP2014508804A5 (OSRAM) | ||
| JP2017538677A5 (OSRAM) | ||
| Gautam et al. | Aerosol technique-based carbon-encapsulated hollow mesoporous silica nanoparticles for synergistic chemo-photothermal therapy | |
| EP2305642A3 (en) | Bis(thio-hydrazide amide) salts for treatment of cancers | |
| JP2016503799A5 (OSRAM) | ||
| JP2013510860A5 (OSRAM) | ||
| JP2011515370A5 (OSRAM) | ||
| HRP20161339T1 (hr) | Konjugati analoga cc-1065 s bifunkcionalnim spojnicama | |
| RU2015126795A (ru) | Минующие нуклеозид киназу композиции и способы их получения и применения |